U.S., Feb. 8 -- ClinicalTrials.gov registry received information related to the study (NCT06813781) titled 'Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004' on Dec. 17, 2024.
Brief Summary: This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD5004 in male and female participants with mild, moderate, and severe hepatic impairment compared with participants with normal hepatic function.
Study Start Date: Dec. 19, 2024
Study Type: INTERVENTIONAL
Condition:
Hepatic Impairment
Intervention:
DRUG: AZD5004
Dose 1
Recruitment Status: RECRUITING
Sponsor: AstraZeneca
Disclaimer: Curat...